Recent advancements in medicine and health revealed that the medical field continues to adapt to changes in the structure of illnesses, therefore arises types per disease. Often, a “one size fits all” treatment would not work on some models, says recent study. Scientists, therefore, have to work on analyzing the build of these different classes and creating a new cure.
Studies show that the use of precision medicine could lessen the use of universal treatments to those which, after several findings, might need a specific kind of treatment. Doctors currently use precision medicine for pancreatic cancer, which is the third leading cause of cancer-related deaths.
Precision medicine refers to a type of treatment based on the structure or the biology of the tumor. The process of analyzing the tumor is called molecular profiling. Doctors study the cancerous matter by collecting a tissue sample through biopsy. The results of the analysis shall determine the treatment one patient should undertake.
In connection, precision medicine involves pharmacogenomics. Pharmacogenomics relates to how genes react under certain drugs. The study includes how to tailor medications to make it more useful for different conditions.
The Pancreatic Cancer Action Network (PanCAN) shared that precision medicine is beneficial especially to those who suffer pancreatic cancer because it personalizes a person’s healing process based on factors such as age, stage of diagnosis, and tumor biology. The features of pancreatic cancer differ from other types of cancer, making it complicated. Therefore, medical experts highly recommend precision medicine as an option.
In their research, PanCAN disputed the fact that the condition of pancreatic cancer patients could not benefit from precision medicine. To back up their statement, they conducted a study among 640 patients. The team performed molecular profiling through their “Know Your Tumor” project and Perthera Precision Medicine.
It showed that those who underwent molecular profiling had a progression-free survival period of an average of 4.1 months. On the other hand, those who had unmatched therapy only have 1.9 months.
The president and CEO of Perthera, Neal Koller, noted that they are still eager to conduct more research regarding the matter and that their output celebrates the patients’ improved health condition and the lives changed by precision medicine.